U.S. Administrative Headquarters
Morris Corporate Center III, 400 Interpace Parkway
Tel: 1 (862) 261-7000
About Allergan, Inc.
Allergan plc (AGN), headquartered in Dublin, Ireland, is a unique, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing innovative branded pharmaceuticals, high-quality generic and over-the-counter medicines and biologic products for patients around the world.
Allergan markets a portfolio of best-in-class products that provide valuable treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates the world's third-largest global generics business, providing patients around the globe with increased access to affordable, high-quality medicines. Allergan is an industry leader in research and development, with one of the broadest development pipelines in the pharmaceutical industry.
We’re Looking for the World’s Best
At Allergan, we are committed to recruiting and retaining the industry’s best and brightest employees and are proud to offer opportunities for military veterans at all levels across our company. We offer business, scientific, technical, engineering, sales & marketing and a variety of other positions here in the U.S. and around the world.
At Allergan, you will find an entrepreneurial style work environment where employees and employee teams are encouraged to apply their unique talents to grow, contribute, innovate and excel. We welcome your ideas. We provide the support, resources and encouragement that enable you to take your career to new heights. We focus on challenging you, challenging ourselves and driving success.
Commit to your future and join us. Learn more about our exciting career opportunities at www.allergan.com/careers.
Founder: Gavin S. Herbert
CEO: Brenton L. Saunders
CFO: Maria Teresa Hilado
Please click here for clinical trial information.
996 articles with Allergan, Inc.
In 2018, the FDA approved 59 novel drugs, meaning approved new molecular entities. BioSpace analyzed new drug approvals from 2014 to 2018 to determine which companies were responsible for the most drug approvals in that period. Here’s a look.
Television Personality Named as Spokesperson for the World's #1 Nonsurgical Fat Reduction Treatment*
Tuesday, January 8, was another busy day in San Francisco for the JP Morgan Healthcare Conference. One interesting sideline was the idea that the current government shutdown could complicate some deals.
In 2015, shares of Allergan were trading at $331.15. This morning, the price of that stock is more than half that price, $145.60 following a 2.2 percent increase after the first day of the J.P. Morgan Healthcare Conference.
Allergan Announces Positive 3-Month Topline Results from Second Phase 3 Study of Bimatoprost SR (Sustained-Release) Implant for Lowering Intraocular Pressure (IOP) in Patients with Open-Angle Glaucoma or Ocular Hypertension
These initial data show the potential for the vast majority of patients to remain treatment free for at least 1 year
The facility, located in Kendall Square, is expected to open in 1Q2019
The white-hot biotech hub of Kendall Square just got a little bit more crowded. Ireland-based Allergan plc announced this morning that the company will establish an R&D facility in the Cambridge, Mass. neighborhood.
New Data Published in the International Journal of Neuropsychopharmacology Support that Rapastinel May Produce Rapid and Sustained Antidepressant Effects Through a Potentially Novel Mechanism of Action
Preclinical research demonstrated rapastinel positively modulates the NMDA receptor
Allergan plc today announced it intends to release fourth quarter and full year 2018 financial results on Tuesday, January 29, 2019, prior to the open of U.S. Financial Markets.
Pharmaceutical companies traditionally adjust the price of drugs twice a year, so it wouldn’t normally be a hot topic. But drug prices have been a controversial subject for several years, especially in politics.
12/28/2018As we look back over the year, we noticed some stories just grabbed readers more than others. Here’s a look at the top 10 stories of the year, including job cuts, best-selling drugs, up-and-coming companies,scandals, clinical trials, and more.
Allergan plc today announced that Chairman and CEO Brent Saunders will present at the 37th Annual J.P. Morgan Healthcare Conference in San Francisco, California.
An analysis shows that more than 30 drugmakers plan to increase the price of prescription medicine in January, despite presidential rhetoric.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allergan plc - AGN
Pomerantz LLP is investigating claims on behalf of investors of Allergan plc
In writing literally hundreds of stories this year, two BioSpace writers, Alex Keown and Mark Terry, found certain stories particularly intriguing or impactful. Some of those were such big topics that they were covered over a series of stories. Looking back at 2018, here are their Top 10.
12/3/2018Biotechs and pharmas strengthened their leadership teams with these appointments. Find news from Mersana, Foamix, Allergan, and more.
Many of these directors do not publicly disclose their affiliation with the pharma companies in their nonprofit biographies, report shows.
Daphne Karydas named Senior VP, Corporate Financial Planning & Analysis and Strategy
Allergan Announces FDA Acceptance of Supplemental New Drug Application for AVYCAZ® (ceftazidime and avibactam)
Application Seeks to Expand the AVYCAZ label to Include Treatment of cUTI and cIAI in Pediatric Patients 3 months of age and older
Allergan plc today announced that Chairman and CEO Brent Saunders will participate in a fireside chat at the 2018 Citi Global Healthcare Conference in New York City.